Related Experiment Video
Updated: Apr 26, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
[Antiplatelet therapy and anticoagulation in acute coronary syndrome: current evidence]
S de Waha1, H Thiele, G Richardt
1Department of Cardiology and Angiology, Heart Center Bad Segeberg, Am Kurpark 1, 23795, Bad Segeberg, Deutschland, s-dw@gmx.net.
Insights
Optimal medical strategies, including potent antiplatelet and anticoagulant therapies, significantly improve outcomes for acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI).
Area of Science:
- Cardiology
- Pharmacology
Context:
- Acute coronary syndrome (ACS) prognosis has improved due to primary percutaneous coronary intervention (PCI).
- Optimal medical management is crucial alongside mechanical reperfusion in ACS.
- Antiplatelet and antithrombotic therapies are vital components of ACS patient care.
Purpose:
- To present data and discuss current evidence on antiplatelet and anticoagulant therapies for ACS patients.
- To highlight advancements in antiplatelet and anticoagulant treatment options.
Summary:
- Newer, potent P2Y12 inhibitors offer advanced antiplatelet options beyond aspirin and clopidogrel.
- Various anticoagulants are available for use before, during, and after PCI, including unfractionated heparin, low molecular weight heparins (e.g., enoxaparin), fondaparinux, and bivalirudin.
- Glycoprotein IIb/IIIa inhibitors may be used adjunctively with anticoagulants.
Impact:
- Improved patient outcomes in ACS through optimized pharmacological strategies.
- Guidance on the selection and use of modern antiplatelet and anticoagulant agents in interventional cardiology.
- Enhanced understanding of the evidence supporting current therapeutic recommendations for ACS management.
Abstract:
In recent years, the prognosis of patients with an acute coronary syndrome (ACS) has significantly improved. This can mainly be attributed to the implementation of primary percutaneous coronary intervention (PCI). Apart from mechanical reperfusion, an optimal medical strategy is of great importance. Antiplatelet and antithrombotic therapies in particular play a crucial role in the management of patients with ACS. New options in antiplatelet therapy are more potent P2Y12 inhibitors in addition to acetylsalicylic acid and clopidogrel. Furthermore, anticoagulant therapy before, during and after PCI can be performed by the use of unfractionated heparin, low molecular weight heparins, such as enoxaparin, the synthetic pentasaccharide fondaparinux and the direct thrombin inhibitor bivalirudin with or without additional administration of glycoprotein IIb/IIIa inhibitors. In this article, data on antiplatelet and anticoagulant therapy are presented and the current evidence is discussed.
Related Concept Videos
Acute Coronary Syndrome IV: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Coronary Artery Disease V: Interprofessional Care
Angina IV: Management
Acute Coronary Syndrome V: Nursing Management
Peripheral Artery Disease III: Interprofessional Care

